Methods of determining the risk of an adverse cardiovascular event or death in a mammal are provided which include determining in a biological sample obtained from the mammal the level of a combination of biomarkers selected from a glucose metabolism biomarker, a heart function biomarker, a renal function biomarker and at least one biomarker of cardiac injury. A score is allotted based on the level of each biomarker, and the cumulative score is indicative of the risk of an adverse cardiovascular event.

The disclosure provides compositions and methods for the detection of renal disease and periodontal disease in mammals.

The present disclosure provides a use of salvianolic acid E (SAE) in the preparation of drugs targeting senescent cells, inhibiting tumors or prolonging lifespan. The inventors are committed to research in screening drugs targeting tumor microenvironment, enhancing the anti-tumor effect of chemotherapeutic drugs, eliminating senescent cells or restraining cellular senescence. Here, it is revealed that salvianolic acid E exerts its effects by targeting tumor microenvironment and eliminating senescent cells. When combined with chemotherapeutic drugs, it shows extremely significant effects in promoting tumor suppression by removing senescent stromal cells. For a senescence-associated secretory phenotype (SASP), the SAE can also effectively target senescent cells so as to inhibit the SASP. Besides, the SAE can also significantly prolong the life of animals, significantly extend the survival period of the old and improve the life quality of animals.

The disclosure provides compositions and methods for the detection of renal disease and periodontal disease in mammals.

Disclosed herein, are compositions, methods, systems, and apparatus for collecting biological material from the nasal cavity of a subject or the olfactory region of a subject's nasal cavity. In some embodiments, the biological material is collected from a targeted sub-region of the nasal cavity, such as a targeted sub-region of the olfactory region, wherein such biological material is specific to the targeted sub-region. In some embodiments, the biological material collected from a targeted sub-region is preserved according to its localization. In some embodiments, the biological material comprises cerebrospinal fluid, one or more microbes of the patient's microbiome, one or more components of the patient's metabolome, one or more pathogens, and/or one or more biomarkers of interest. In some embodiments, a specific formulation is delivered to the region in the nasal cavity for facilitating biological material collection located therein.

The present invention relates to a method for determining, predicting or estimating the biological age of a subject, or for providing a measurement for use in determining, predicting or estimating the biological age of a subject or for predicting the presence or absence of at least one disease in a subject, predicting the risk of a subject of having or developing at least one disease; and/or predicting the risk of mortality of a subject. This invention also relates to a device for determining the presence and/or amount of each biomarker in a set of biomarkers; a set of probes for determining the presence or amount of a set of biomarkers, and the use of such device and/or probes in any of the above methods. Also provided is a biomarker testing kit for use in a method as described herein and a computer-readable storage medium or a computer program comprising computer-executable instructions and associated method.

The precision of a lateral flow assay for determining the concentration of an analyte in the plasma fraction of a sample of whole blood can be significantly improved by applying an integrated step for determining the hematocrit of the optionally diluted sample, and taking both hematocrit and dilution factor into account when calculating the concentration of the analyte. This is made possible inter alia by using a predetermined wavelength when taking an image of the sample after application to a substrate in the lateral flow assay device, and wherein said wavelength is selected based on the dilution factor used. This hematocrit measurement is advantageously integrated in lateral flow assay methods and devices for the measurement of an analyte in plasma and contributes significantly to an improved precision of such assays.